The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
IBD Diagnosis. Monitoring, and Prediction of Complications
Date
May 18, 2024
SOCIETY: AGA This session highlights the latest research on novel prediction models in IBD as well as the role of the fecal microbiome and imaging in IBD.
Presentations:
DEVELOPMENT AND VALIDATION OF AN INTEGRATED RISK SCORE FOR PREDICTING FUTURE RISK OF CROHN'S DISEASE UP TO 7 YEARS BEFORE DIAGNOSIS IN HEALTHY FIRST-DEGREE RELATIVES: THE CCC-GEM PROJECT, A MULTICENTRE PROSPECTIVE COHORT STUDY
FAECAL MICROBIOME AS TARGETED NON-INVASIVE BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE: A CROSS-POPULATION METAGENOMIC ANALYSIS IN SIX COHORTS
COMPARISON OF DIAGNOSTIC ACCURACY BETWEEN CROSS SECTIONAL IMAGING TECHNIQUES AND SMALL INTESTINAL CONTRAST ULTRASONOGRAPHY IN SMALL BOWEL CROHN’S DISEASE (THE CACTUS-CD TRIAL) : A PAIRED VALIDATING CONFIRMATORY STUDY
EARLY INTESTINAL ULTRASOUND RESPONSE TO BIOLOGIC AND SMALL MOLECULE THERAPY PREDICTS ENDOSCOPIC OUTCOMES IN CHILDREN WITH ULCERATIVE COLITIS
A CLINICAL SCORE FOR UC2CD, A NOVEL SUBGROUP IN INFLAMMATORY BOWEL DISEASES (IBD) WITH DISTINCT SEROLOGICAL, GENETIC AND CLINICAL FEATURES
SIMPLE ENDOSCOPIC SCORE FOR CROHN’S DISEASE (SES-CD) ≥ 7 PREDICTS DISEASE PROGRESSION IN PATIENTS WITH MILD CD
SOCIETY: AGA By popular demand, this new session highlights the best late-breakers submitted to the IBD section and well as innovations in technology and new paradigms of care in IBD
SOCIETY: AGA Small molecules are a new exicting therapeutic class in IBD that may have potential safety signals which have not been well described in the real world…
SOCIETY: AGA In this session, several clinically relevant presentations will put the attendee at the cutting edge of research and clinical care, with regard to stem cells for perinal fistulas, biologic de-escalation, subcutaneous biologics, and use of small molecules in microscopic colitis